Lung transplantation cases
| Case | Type of cancer | Allograft outcome | Checkpoint inhibitor | Year from tx to ICI | IS regimen | Cancer response | Interval between IS reduction and ICI initiation | ICI to event time |
|---|---|---|---|---|---|---|---|---|
| Tsung et al. (2021) [24] | cSCC | Immune-mediated pneumonitis (recovered) | Cemiplimab×2 | 10.8 | Tac, Pred 5 mg | CR | NA | After 2 cycles of cemiplimab |
| Daud et al. (2020) [82] | cSCC | Chronic allograft dysfunction | Pembrolizumab | 4 | Tac, MMF, Pred | NA | NA | |
| Melanoma | Acute allograft dysfunction | Ipilimumab | 14 | Tac, Pred | NA | NA |
tx, transplantation; ICI, immune checkpoint inhibitor; IS, immunosuppressant; cSCC, cutaneous squamous cell carcinoma; Tac, tacrolimus; Pred, prednisone; CR, complete response; NA, not applicable; MMF, mycophenolate mofetil.